Effect of Mylanta on naproxen bioavailability.
The effect of Mylanta on naproxen bioavailability was studied in 11 healthy volunteers. In separate experiments, single oral doses of naproxen (250 mg) and multiple oral doses (250 mg twice daily for 7 days) were administered with and without Mylanta. Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr). There was no significant difference between trough level naproxen concentrations at steady state (29.6 microgram/ml with Mylanta vs. 30.7 microgram/ml without Mylanta). The data were also used to investigate naproxen pharmacokinetics predicted by two different pharmacokinetic models, one of which allowed for protein binding. The nonlinear protein-binding model accurately predicted steady-state concentration, while the values predicted by the linear model exceeded actual values by 33-54%.
D000328:Adult; D000536:Aluminum Hydroxide / Q000494:pharmacology*; D000863:Antacids / Q000494:pharmacology*; D001682:Biological Availability; D004338:Drug Combinations / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008274:Magnesium / Q000494:pharmacology*; D008276:Magnesium Hydroxide / Q000494:pharmacology*; D008297:Male; D009288:Naproxen / Q000378:metabolism*; D012828:Silicones / Q000494:pharmacology*; D012841:Simethicone / Q000494:pharmacology*; D013997:Time Factors
D000863:Antacids; D004338:Drug Combinations; D012828:Silicones; C008570:aluminum hydroxide, magnesium hydroxide, simethicone drug combination; D009288:Naproxen; D000536:Aluminum Hydroxide; D012841:Simethicone; D008274:Magnesium; D008276:Magnesium Hydroxide